ASP1517 Phase 2 Clinical Trial -A Multi-center, Randomized, Parallel Groups, Placebo-controlled, Double-Blind Study of ASP1517 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis

Trial Profile

ASP1517 Phase 2 Clinical Trial -A Multi-center, Randomized, Parallel Groups, Placebo-controlled, Double-Blind Study of ASP1517 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2016

At a glance

  • Drugs Roxadustat (Primary)
  • Indications Anaemia
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 08 Nov 2016 According to FibroGen media release, results from this study will be presented at the American Society of Nephrology's Kidney Week in November 2016.
    • 25 Jul 2016 Primary endpoint (Haemoglobin level (Rate of rise in Hb (g/dL/week) at Week 6 [Time Frame: Baseline and at 6 weeks after dosing])) has been met, as reported in an Astellas Pharma media release.
    • 25 Jul 2016 Results published in an Astellas Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top